{
 "as_of": "2026-11-06",
 "cmr": "uk-cm-kg/AIM/AREC",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# ARECOR THERAPEUTICS PLC (AIM: AREC) — research page\n\nAs of 2026-11-06 · uk-cm-kg · record version 1\n\n## Identity and listing\n\nARECOR THERAPEUTICS PLC is listed on AIM under the ticker AREC, with ISIN GB00BMWLM973 and LEI 98450093D12I3A8DDD58. Its security type on the record is Corporate, its segment is ASQ1, its sector is Pharmaceuticals and Biotechnology [201030], and its jurisdiction is England and Wales (Companies House jurisdiction field). The record holds its status as listed, not halted.\n\n## The disclosure read\n\nThe record holds 26 filings across 22 filing days in the twelve months to 2026-11-06. The median gap between filing days is 7 days. The latest filing is dated 2026-10-15, 22 days before the record date, and is a regulatory announcement. The AIM median cadence gap is 7.0 days across 594 issuers, and the AIM median latency is 4 days. The Pharmaceuticals and Biotechnology [201030] median cadence gap is 6.0 days across 51 issuers, and its median latency is 4.0 days.\n\n## Auditor\n\nThe auditor of record is PKF Littlejohn LLP. Its location is not on the record. Auditor changes are not on the record.\n\n## Events and halts\n\nListing, delisting, name change, domicile change and segment move dates are not on the record, because no lifecycle type map is yet in place for this register. The halt flag is listed, not halted.\n\n## Orderability\n\nFor elective professional client, the signal is ACM-200 and the outcome is determinable. For eligible counterparty, the signal is ACM-200 and the outcome is determinable. The rule version is acm-68000/uk/product-governance-fca-prod-sourcebook/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nNo research houses were found on the issuer's investor-relations pages that were read.\n\n## Open research\n\nThree openly published research notes are on the record, all by Trinity Delta: dated 2024-01-24, 2024-03-13 and 2024-07-23.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nNo years of the issuer are sealed, and the market's vintage is not sealed. The live record began on 2026-09-11. Sealed years exist in the store for 2021 through 2026 but are not served as of a date, and the as-of door answers not_sealed.\n\n## Sources\n\n13 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.londonstockexchange.com/live-markets/market-data-dashboard/price-explorer (identity.exchange)\n- https://api.londonstockexchange.com/api/gw/lse/instruments/alldata/AREC (identity.isin)\n- https://find-and-update.company-information.service.gov.uk/company/13331147 (identity.jurisdiction)\n- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)\n- https://www.londonstockexchange.com/stock/AREC/arecor-therapeutics-plc/company-page (identity.sector)\n- https://mcp.uk-cm-kg.ai/events/AIM/AREC (the disclosure lines)\n- https://marketsecurities.fca.org.uk/officiallist (the halt flag)\n- https://arecor.com/wp-content/uploads/2025/05/270269-Arecor-Therapeutics-AR-WEB.pdf (the auditor)\n- https://mcp.uk-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://arecor.com/wp-content/uploads/2024/07/AREC-Lighthouse-240723.pdf (open research)\n- https://arecor.com/wp-content/uploads/2024/03/2024-03-13-TRx-co-development-deal-centred-on-oral-GLP-1-product.pdf (open research)\n- https://arecor.com/wp-content/uploads/2024/01/AREC-Lighthouse-240124.pdf (open research)\n- https://mcp.uk-cm-kg.ai/record/AIM/AREC (the record)\n",
 "market": "UK",
 "node": "uk-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [],
   "live_record_began": "2026-09-11",
   "node_history_from": null,
   "node_years_sealed": [],
   "note": "6 years are sealed in the UK store; their Replay split is not built, so the as-of door answers not_sealed and the record is the live record as of 2026-11-06",
   "record_version": 1,
   "sealed": false,
   "store_years_sealed_not_served": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ]
  },
  "auditor": {
   "auditor": {
    "read_by": "Tavily regex · adjudicated by Claude",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://arecor.com/wp-content/uploads/2025/05/270269-Arecor-Therapeutics-AR-WEB.pdf",
    "state": "filled",
    "value": "PKF Littlejohn LLP"
   },
   "auditor_firm_id": {
    "market": "UK",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "UK",
    "state": "not_on_record"
   },
   "changes": {
    "market": "UK",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "cmr": "uk-cm-kg/AIM/AREC",
  "coverage": {
   "count": 0,
   "houses": [],
   "pages_checked": [
    {
     "page": "https://arecor.com/investor-centre/faqs-and-help/",
     "result": "read: 1 of 1 named houses found on the page; the page does not name the issuer"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-12",
   "since": null,
   "state": "none_found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 594,
     "median_cadence_gap_days": 7,
     "median_filings": 33.5,
     "median_latency_days": 4,
     "name": "AIM"
    },
    "sector": {
     "issuers": 51,
     "median_cadence_gap_days": 6,
     "median_filings": 42,
     "median_latency_days": 4,
     "name": "Pharmaceuticals and Biotechnology [201030]"
    }
   },
   "by_type": {
    "agm_record_date": 1,
    "ch_accounts_filed": 1,
    "ch_capital": 1,
    "ch_confirmation_statement": 1,
    "ch_officer_change": 1,
    "director_dealing": 1,
    "early_warning": 7,
    "financial_statement": 3,
    "regulatory_announcement": 10
   },
   "cadence_median_gap_days": 7,
   "filing_days": 22,
   "filings": 26,
   "latency_days": 22,
   "latest": [
    {
     "category": null,
     "date": "2026-10-15",
     "source": "https://www.investegate.co.uk/announcement/rns/arecor-therapeutics--arec/patents-for-concentrated-ultra-rapid-insulins/9823649",
     "title": "Patents for concentrated ultra-rapid insulins",
     "type": "regulatory_announcement"
    },
    {
     "category": null,
     "date": "2026-10-14",
     "source": "https://find-and-update.company-information.service.gov.uk/company/13331147/filing-history/MzU1MDk0NTE2NWFkaXF6a2N4/document?format=pdf&download=0",
     "title": "capital allotment shares — 2026-10-08",
     "type": "ch_capital"
    },
    {
     "category": null,
     "date": "2026-10-13",
     "source": "https://www.investegate.co.uk/announcement/rns/arecor-therapeutics--arec/holding-s-in-company/9820217",
     "title": "Holding(s) in Company",
     "type": "early_warning"
    },
    {
     "category": null,
     "date": "2026-10-13",
     "source": "https://www.investegate.co.uk/announcement/rns/arecor-therapeutics--arec/holding-s-in-company/9820194",
     "title": "Holding(s) in Company",
     "type": "early_warning"
    },
    {
     "category": null,
     "date": "2026-10-08",
     "source": "https://www.investegate.co.uk/announcement/rns/arecor-therapeutics--arec/holding-s-in-company/9813719",
     "title": "Holding(s) in Company",
     "type": "early_warning"
    }
   ],
   "latest_filing_date": "2026-10-15",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.uk-cm-kg.ai/events/AIM/AREC",
   "window": {
    "from": "2025-11-06",
    "to": "2026-11-06"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "LSE price explorer (exchange list)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://www.londonstockexchange.com/live-markets/market-data-dashboard/price-explorer (price-explorer feed api.londonstockexchange.com/api/v1/components/refresh, markets=AIM, categories=EQUITY, showonlylse=true)",
    "state": "sourced",
    "value": "AIM"
   },
   "isin": {
    "read_by": "LSE instrument reference record (exchange site)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://api.londonstockexchange.com/api/gw/lse/instruments/alldata/AREC",
    "state": "confirmed",
    "value": "GB00BMWLM973"
   },
   "jurisdiction": {
    "read_by": "Companies House REST API (company profile) (jurisdiction field)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://find-and-update.company-information.service.gov.uk/company/13331147",
    "state": "confirmed",
    "value": "England and Wales (Companies House jurisdiction field)"
   },
   "lei": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (daily), LEI by exact ISIN",
    "read_date": "2026-11-09",
    "read_date_basis": "the field",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download (ISIN GB00BMWLM973)",
    "state": "sourced",
    "value": "98450093D12I3A8DDD58"
   },
   "name": {
    "read_by": "LSE price explorer (exchange list)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://www.londonstockexchange.com/live-markets/market-data-dashboard/price-explorer (price-explorer feed api.londonstockexchange.com/api/v1/components/refresh, markets=AIM, categories=EQUITY, showonlylse=true)",
    "state": "sourced",
    "value": "ARECOR THERAPEUTICS PLC"
   },
   "sector": {
    "read_by": "LSE issuer profile (exchange site)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://www.londonstockexchange.com/stock/AREC/arecor-therapeutics-plc/company-page",
    "state": "sourced",
    "value": "Pharmaceuticals and Biotechnology [201030]"
   },
   "security_type": {
    "read_by": "LSE price explorer (exchange list)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://www.londonstockexchange.com/live-markets/market-data-dashboard/price-explorer (price-explorer feed api.londonstockexchange.com/api/v1/components/refresh, markets=AIM, categories=EQUITY, showonlylse=true)",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "read_by": "LSE price explorer (exchange list)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://www.londonstockexchange.com/live-markets/market-data-dashboard/price-explorer (price-explorer feed api.londonstockexchange.com/api/v1/components/refresh, markets=AIM, categories=EQUITY, showonlylse=true)",
    "state": "sourced",
    "value": "ASQ1"
   },
   "ticker": {
    "read_by": "LSE price explorer (exchange list)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://www.londonstockexchange.com/live-markets/market-data-dashboard/price-explorer (price-explorer feed api.londonstockexchange.com/api/v1/components/refresh, markets=AIM, categories=EQUITY, showonlylse=true)",
    "state": "sourced",
    "value": "AREC"
   },
   "website": {
    "read_by": "LSE issuer profile (exchange site)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://www.londonstockexchange.com/stock/AREC/arecor-therapeutics-plc/company-page",
    "state": "sourced",
    "value": "www.arecor.com"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": {
    "market": "UK",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "domicile_change": {
    "market": "UK",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "listing": {
    "market": "UK",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "name_change": {
    "market": "UK",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "segment_move": {
    "market": "UK",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "market": "UK",
  "node": "uk-cm-kg",
  "numbers_hash": "sha256:c8d5e18d0f5137f1a295b0571e356dd40638a08eb291ee5de56c6e101f14020a",
  "open_research": {
   "read_date": "2026-11-12",
   "rows": [
    {
     "date": "2024-07-23",
     "kind": "issuer-sponsored",
     "publisher": "Trinity Delta",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-12",
     "source": "https://arecor.com/wp-content/uploads/2024/07/AREC-Lighthouse-240723.pdf",
     "state": "sourced",
     "title": "Funding growth; diabetes still the key value driver"
    },
    {
     "date": "2024-03-13",
     "kind": "issuer-sponsored",
     "publisher": "Trinity Delta",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-12",
     "source": "https://arecor.com/wp-content/uploads/2024/03/2024-03-13-TRx-co-development-deal-centred-on-oral-GLP-1-product.pdf",
     "state": "sourced",
     "title": "TRx co-development deal centred on oral GLP-1 product"
    },
    {
     "date": "2024-01-24",
     "kind": "issuer-sponsored",
     "publisher": "Trinity Delta",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-12",
     "source": "https://arecor.com/wp-content/uploads/2024/01/AREC-Lighthouse-240124.pdf",
     "state": "sourced",
     "title": "Sanofi deal for INBRX-101 validates Arestat technology"
    }
   ],
   "state": "found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [
    "elective professional client",
    "eligible counterparty"
   ],
   "outcomes": {
    "elective professional client": {
     "determinable": true,
     "signal": "ACM-200"
    },
    "eligible counterparty": {
     "determinable": true,
     "signal": "ACM-200"
    }
   },
   "read": {
    "basis": "one live read per instrument class, halt state and client category on this market; this issuer's group",
    "chapter": "https://mcp.uk-cm-kg.ai/book/aio.json",
    "door": "https://mcp.uk-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "rule_version": "acm-68000/uk/product-governance-fca-prod-sourcebook/r1",
   "section": "uk.aio.v16"
  },
  "record": {
   "as_of": "2026-11-06",
   "url": "https://mcp.uk-cm-kg.ai/record/AIM/AREC",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-09",
   "source": "https://marketsecurities.fca.org.uk/officiallist",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:c8d5e18d0f5137f1a295b0571e356dd40638a08eb291ee5de56c6e101f14020a",
 "path": "/uk/AIM/AREC",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "ARECOR THERAPEUTICS PLC is listed on AIM under the ticker AREC, with ISIN GB00BMWLM973 and LEI 98450093D12I3A8DDD58. Its security type on the record is Corporate, its segment is ASQ1, its sector is Pharmaceuticals and Biotechnology [201030], and its jurisdiction is England and Wales (Companies House jurisdiction field). The record holds its status as listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 26 filings across 22 filing days in the twelve months to 2026-11-06. The median gap between filing days is 7 days. The latest filing is dated 2026-10-15, 22 days before the record date, and is a regulatory announcement. The AIM median cadence gap is 7.0 days across 594 issuers, and the AIM median latency is 4 days. The Pharmaceuticals and Biotechnology [201030] median cadence gap is 6.0 days across 51 issuers, and its median latency is 4.0 days.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is PKF Littlejohn LLP. Its location is not on the record. Auditor changes are not on the record.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "Listing, delisting, name change, domicile change and segment move dates are not on the record, because no lifecycle type map is yet in place for this register. The halt flag is listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "For elective professional client, the signal is ACM-200 and the outcome is determinable. For eligible counterparty, the signal is ACM-200 and the outcome is determinable. The rule version is acm-68000/uk/product-governance-fca-prod-sourcebook/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "No research houses were found on the issuer's investor-relations pages that were read.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "Three openly published research notes are on the record, all by Trinity Delta: dated 2024-01-24, 2024-03-13 and 2024-07-23.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "No years of the issuer are sealed, and the market's vintage is not sealed. The live record began on 2026-09-11. Sealed years exist in the store for 2021 through 2026 but are not served as of a date, and the as-of door answers not_sealed.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "13 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.londonstockexchange.com/live-markets/market-data-dashboard/price-explorer"
  },
  {
   "for": "identity.isin",
   "source": "https://api.londonstockexchange.com/api/gw/lse/instruments/alldata/AREC"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://find-and-update.company-information.service.gov.uk/company/13331147"
  },
  {
   "for": "identity.lei",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download"
  },
  {
   "for": "identity.sector",
   "source": "https://www.londonstockexchange.com/stock/AREC/arecor-therapeutics-plc/company-page"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.uk-cm-kg.ai/events/AIM/AREC"
  },
  {
   "for": "the halt flag",
   "source": "https://marketsecurities.fca.org.uk/officiallist"
  },
  {
   "for": "the auditor",
   "source": "https://arecor.com/wp-content/uploads/2025/05/270269-Arecor-Therapeutics-AR-WEB.pdf"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.uk-cm-kg.ai/book/aio.json"
  },
  {
   "for": "open research",
   "source": "https://arecor.com/wp-content/uploads/2024/07/AREC-Lighthouse-240723.pdf"
  },
  {
   "for": "open research",
   "source": "https://arecor.com/wp-content/uploads/2024/03/2024-03-13-TRx-co-development-deal-centred-on-oral-GLP-1-product.pdf"
  },
  {
   "for": "open research",
   "source": "https://arecor.com/wp-content/uploads/2024/01/AREC-Lighthouse-240124.pdf"
  },
  {
   "for": "the record",
   "source": "https://mcp.uk-cm-kg.ai/record/AIM/AREC"
  }
 ],
 "title": "ARECOR THERAPEUTICS PLC (AREC) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}